The U.S. government on Tuesday named the 15 new drugs targeted for Medicare price negotiations for 2028, including Gilead ...
The striking benefits achieved with emerging treatment options for recalcitrant connective tissue diseases offer the ...
Jan 27 (Reuters) - The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs ...
Boehringer Ingelheim has added another drug to its immunology pipeline, licensing an inflammatory bowel disease (IBD) ...
AI and genetics are creating a 'seismic shift' in the pharmaceutical business, experts on Asian Financial Forum panel say ...
Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody. | Boehringer Ingelheim has penned a 1.
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...
The AHA Jan. 26 urged the Health Resources and Services Administration to take immediate action to stop a new Eli Lilly and ...
The American Hospital Association is asking the Trump administration to stop Eli Lilly from enacting a new policy as part of ...
The ongoing surge in licensing deals for early drug prospects should continue this year and involve more cell and gene ...
The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results